Scarica l'app Stockscreener
8.09
1.00%
0.08
Pre-mercato:
8.19
0.10
+1.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Precedente Chiudi:
$8.01
Aprire:
$8.13
Volume 24 ore:
543.81K
Relative Volume:
0.61
Capitalizzazione di mercato:
$1.27B
Reddito:
$61.10M
Utile/perdita netta:
$-138.36M
Rapporto P/E:
-5.9926
EPS:
-1.35
Flusso di cassa netto:
$-90.59M
1 W Prestazione:
+2.93%
1M Prestazione:
-4.82%
6M Prestazione:
+3.06%
1 anno Prestazione:
+110.13%
Intervallo 1D:
$7.96
$8.13
Intervallo di 1 settimana:
$7.96
$8.38
Portata 52W:
$3.85
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Nome
Ocular Therapeutix Inc
Settore
Industria
Telefono
781-357-4000
Indirizzo
15 CROSBY DRIVE, BEDFORD, MA
Confronta OCUL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.09 | 1.27B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-20 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-02-09 | Iniziato | BofA Securities | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-10 | Ripresa | Berenberg | Buy |
| 2021-08-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-11-13 | Reiterato | Raymond James | Strong Buy |
| 2020-08-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-05-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Iniziato | Raymond James | Strong Buy |
| 2018-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-07-12 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-08-11 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire
RoundAngle Advisors LLC Invests $1.70 Million in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) and Verona Pharma (NASDAQ:VRNA) Financial Contrast - Defense World
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ocular Therapeutix Grants Stock Options and RSU Awards to New Employee in Incentive Plan - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Ocular Therapeutix (STU:0OT) Cash From Discontinued Investi - GuruFocus.com
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR - GlobeNewswire
Ocular Therapeutix progresses with AXPAXLI trials for eye diseases By Investing.com - Investing.com Canada
Ocular Therapeutix progresses with AXPAXLI trials for eye diseases - Investing.com India
Ocular Therapeutix Advances AXPAXLI Eye Treatment Trials with Strong Enrollment Milestone - StockTitan
Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | - openPR
Investors push Ocular Therapeutix (NASDAQ:OCUL) 6.3% lower this week, company's increasing losses might be to blame - Simply Wall St
Learn to Evaluate (OCUL) using the Charts - Stock Traders Daily
OCULOcular Therapeutix, Inc. Latest Stock News & Market Updates - StockTitan
Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - The Manila Times
Ocular Therapeutix™ to Provide Corporate Update During 43rd - GlobeNewswire
Ocular Therapeutix CEO to Present AXPAXLI Trial Updates at J.P. Morgan Healthcare Conference - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Principal Financial Group Inc. - Defense World
EyePoint initiated at buy by Citi on wAMD drug potential - MSN
Ocular Stock Is Now Thoroughly Derisked (NASDAQ:OCUL) - Seeking Alpha
Long Term Trading Analysis for (OCUL) - Stock Traders Daily
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Geode Capital Management LLC - MarketBeat
Geode Capital Management LLC Has $28.46 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 2.5%Time to Sell? - MarketBeat
State Street Corp Has $30.24 Million Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Barclays PLC Has $4.45 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
State Street Corp Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Last Week's Biggest Stock Movers: Mylan, Ocular Therapeutix - AOL
Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week - Yahoo Finance
How to Take Advantage of moves in (OCUL) - Stock Traders Daily
Wellington Management Group LLP Purchases 148,310 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
BNP Paribas Financial Markets Sells 19,513 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
Fmr LLC Purchases 428,335 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix Grants Major Stock Awards Package to New Executive, Including 285K Shares - StockTitan
Verition Fund Management LLC Purchases Shares of 62,501 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Ocular Therapeutix CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Charles Schwab Investment Management Inc. Has $9.66 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Point72 Asset Management L.P. Trims Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
492,900 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Bought by Polar Asset Management Partners Inc. - MarketBeat
HC Wainwright Reaffirms Buy Rating for Ocular Therapeutix (NASDAQ:OCUL) - Defense World
235,498 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Patient Square Capital LP - MarketBeat
Erste Asset Management GmbH Makes New $2.05 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix Inc Azioni (OCUL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):